Immunological significances of invariant chain from the aspect of its structural homology with the cystatin family  by Katunuma, Nobuhiko et al.
FEBS Letters 349 (1994) 265-269 
FEBS 14271 
Immunological significances of invariant chain from the aspect of its 
structural homology with the cystatin family 
Nobuhiko KatunumaaT*, Hisao Kakegawa”, Youichi Matsunagab, Toshiji Saibara” 
“Institute for Health Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770. Japan 
bThird Department of Internal Medicine, School of Medicine, The University of Tokushima, Tokushima 770, Japan 
“Department of First Internal Medicine, The Kochi Medical School, Kochi 783. Japan 
Received 2 June 1994 
Abstract 
The primary structure of p31 of invariant chain (Ii-chain) shows about 50% homology with those of the cystatin family which are endogenous 
cysteine protease inhibitors. The binding domains between Ii-chain and HLA-DR-7 were estimated from the structural homology between cystatin 
and Ii-chain and also between cathepsins and DR-7, respectively. The QL%,, and GS7c_8, of Ii-chain were estimated to be the binding domains with 
GGd>j, and VS57-63 of HLA-DR7, respectively. The purified human Ii-chain from spleen is capable of forming four molecular forms from monomer 
to tetramer by redox-potential dependent disulfide bond formation. The Ii-chain inhibits cathepsin L and H competitively as a dimer and the K, value 
for cathepsin L was 4.1 x IO-* M, but cathepsin B was not inhibited at all. The Ii-chain showed mainly a dimer (60 kDa) under the assay condition 
of cathepsins with cysteine and was not degraded by these cathepsins. The Ii-chain may play an important role in the regulation of antigenic peptide 
presentation to MHC class II. 
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1. Introduction 
We have reported previously that lysosomal cathepsin 
B of macrophages plays an essential role in the process- 
ing of some exogenous antigens to present with MHC 
class II [1,2]. The immune responses to virus vaccines of 
hepatitis B and rabies as antigens were suppressed by 
specific inhibitors of cathepsin B (E-64 [3] and CA-074 
[4]), anti-cathepsin B antibody [21] and specific substrate 
of cathepsin B [30]. Furthermore, one of the active sites 
of cathepsin B [5,6], VN2,,_222 shares high homology with 
a part of the desetope, VN57-62 of the HLA-DR7 [7,8]. 
This evidence suggests that the fragments formed from 
antigens by selective proteolysis of cathepsin B are capa- 
ble of binding commonly with the desetope of MHC 
class II, B-chain. We found that the amino acid sequence 
of the Ii-chain shares high homology with that of the 
cystatin family which are the endogenous inhibitors of 
cathepsins and the Ii-chain strongly inhibits the activities 
of cathepsins. We first purified the Ii-chain from human 
spleen and the properties and the molecular forms were 
studied. Herein we discuss a new aspect of immunologi- 
cal significance of Ii-chain in the regulation of antigenic 
peptide presentation to MHC class II. 
2. Materials and methods 
2. I. Materials 
The substrates for cathepsins, Z-Arg-Arg-MCA, Z-Phe-Arg-MCA 
and Arg-MCA were purchased from Institute for Protein Research, 
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Peptide Inst. Inc., Osaka. Cathepsin B and L were purified from rat 
liver by Katunuma’s method [24,25]. Silver staining kit was purchased 
from Wako Pure Chemical Co., Japan. The mouse antibody against 
CD74 as a first antibody was purchased from The Binding Site Ltd., 
USA and anti-human CD74 (LN-2) as a first antibody was purchased 
from Seikagaku Co., Japan. Goat anti-mouse IgG Fab’-conjugated 
alkaline phosphatase was purchased from EY Laboratories Inc. and 
picoBlue Immunoscreening Kits from Stratagene, CA. Sephadex G-75, 
DEAE-Sepharose FF and Superdex 200HR lo/30 were purchased from 
Pharmacia and YM-IO membrane from Amicon, Japan and Jasco- 
HPLC system from Jasco Co., Japan were used. 
2.2. Enzyme assay 
Various cysteine protease activities were measxured with Z-Arg-Arg- 
MCA for cathepsin B, Z-Phe-Arg-MCA for cathepsin L plus B and 
Arg-MCA for cathepsin H at pH 5.5 by the method of Barrett and 
Kirschke [30]. Purified Ii-chains were briefly preincubated with cathep- 
sin and the reactions were started by the addition of the relevant sub- 
strates. The fluorescence of 7-amine-4-methylcoumrin (MCA) liberated 
from substrates were monitored by a fluorescence spectrometer 
(Hitachi F-2000). Protein concentration in the reaction mixtures were 
determined by the BCA method (Pierce Chemical Co., Rockford, IL) 
with bovine serum albumin as a standard. 
2.3. Gel electrophoresis and western blotting analysis of Ii-chain 
SDS-PAGE was carried out by the method of Laemmli [19] in a 
15-25% gradient gel containing 0.1% SDS at room temperature. The 
Ii-chain (400 ng) was incubated with and without 500 pg of 2-mercap- 
toethanol for 10 min at room temperature or 100°C in the same buffer. 
The gel was stained with silver stain kit and the immunoblotting was 
developed using a mouse antibody against human CD74 as a first 
antibody and the anti-human CD74 (LN-2) was also used as a first 
antibody. The bound antibodies were detected by goat anti-mouse IgG 
Fab’conjugated alkaline phosphatase and the alkaline phosphatase 
reaction was performed using picoBlue Immunoscreening Kits. The 
SDS-PAGE molecular weight markers (Bio-Rad, Richmond) were bo- 
vine serum albumin (80 kDa), ovalbumin (49.5 kDa), carbonic anhy- 
drase (32.5 kDa) and soybean trypsin inhibitor (27.5 kDa). 
2.4. Search for sequence homology between Ii-chain and cystatin family 
Optimal pairwise alignments were calculated by use of computer 
implementation using GENETYX ver.7.0 (Software Development, 
Tokyo, Japan). The homological part of amino acid sequences between 
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Human Ii MHRRRSRSCREDQKP total sequences of cystatins and p31 of human Ii-chain were compared 
and the homology matching was calculated under the consideration of 
X-ray co-crystal structure of cystatin B and cathepsin B [27]. 
3. Results and discussion 
3.1. Homology of amino acid sequences between Ii-chain 
and cystatin family and possible binding domains 
between Ii-chain and HLA-DR7 
The amino acid sequence of human Ii-chain has been 
reported as 232 amino acid residues by gene cloning [9]. 
The human Ii-chain contains 2 mol of cysteines located 
near N-terminus, whereas the mouse and rat Ii-chains 
contain only 1 mol of cysteine and the sorting signal 
motif of EP,,_,, for introduction to the endosome is also 
located near N-terminus [lo]. The N-terminus domain of 
p3 1 in Ii-chain [ 16,171 shows more than 50% homology 
with that of the cystatin family [l l-151 as shown in Fig. 
1. The homology search of their sequence matching be- 
tween cystatin family and Ii-chains was calculated by 
computer implementation under consideration of X-ray 
co-crystal structure of cystatin B with cathepsin B [27]. 
Although the Ii-chain contains sugar unlike the cystatin 
family, it may be considered to belong to the cystatin 
super family. The sequences of cystatin B, QL,,, and 
GS 7ca3 which bind with the two active sites of cathepsin 
B [6] show the highest homology with two domains of 
Ii-chain, QL,,, and GS7c83, respectively. As mentioned 
previously, the two domains of active sites of cathepsin 
B, GG19s215 and VT217m223 show significant homology 
with those of the desetope of HLA-DR7 [16], GG,,_,, 
and VS,,_,,, respectively. Therefore, these two domains 
of Ii-chain, QLw7, and GS,,*, are estimated to be the 
binding domains with those of the desetope of HLA- 
DR7, GG,,_,, and VS,,_,,, respectively. The stereo- 
structures of cathepsin B-cystatin P-co-crystal [6,27] and 
crystal of MHC class II [18] by X-ray crystallography 
also support our hypothesis proposed on the binding 
domains between Ii-chain and HLA-DR7, as illustrated 
in Fig. 2. Furthermore, it was reported recently that the 
two complexes between MHC class II b-chain and a part 
of Ii-chain, that is, 96-122 domain of Ii-chain plus HLA- 
DRl and 96112 domain plus HLA-DR3, were isolated 
[28,29]. These domains of Ii-chain correspond to the 
binding domain with HLA-DR7, /?-chain estimated. 
3.2. Purification of human Ii-chain from spleen 
We first purified the Ii-chain from human spleen, and 
the properties and the interconvertible molecular forms 
were studied. Homogenized human spleen in 20 mM 
Tris-HCl buffer, pH 7.5, was sonicated. The supernatant 
after centrifugation was treated with O-70% of 
(NH&SO,. The precipitate was applied to a column of 
Sephadex G-75. The fractions containing Ii-chain de- 
tected using immunoblotting analysis were concentrated 
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Fig. 1. Sequence homology between Ii-chain and the cystatin family. 
Sequence homology between total sequences of cystatins and p3l of 
human Ii-chain were compared. The entrenched symbols indicate ho- 
mologous (or same) sequences between Ii-chain and the cystatin family. 
Two domains of cystatin B, QL,,_,, and GS,,,, to bind with active sites 
of histidine-199 area and asparagine-217 area which are substrate bind- 
ing sites of cathepsin B show the highest homology with the correspond- 
ing two domains of Ii-chain, QL,,, and GS,,.,,, respectively, and these 
domains, illustrated by shadow lines, seem to be the binding domains 
with the HLA-DR7. ****EQLP shows the sorting signal sequence of 
Ii-chain into lysosome. 
by YM-10 membrane. The Ii-chain fraction was then 
applied to a DEAE-Sepharose FF column and the non- 
absorbed eluents with the same buffer were collected. 
The eluent was then applied to a solumn of Superdex 200 
HR lo/30 connected in series with a Jasco HPLC system 
equilibrated with the same buffer containing 0.2 M 
Na,SO,. Two protein peaks were eluted from the column 
and Ii-chain was eluted in the first peak corresponding 
to 120 kDa. Finally, the Ii-chain was purified by the 
repeated HPLC as a single peak. Then, the purified Ii- 
chain were subjected to SDS-PAGE (lo-20% gradient 
gel containing 0.1% SDS) by the modified method of 
Laemmli [19]. The gels were stained with silver stain kit 
and the immunoblotting was developed using the anti- 
body against Ii-chain mentioned in section 2. All positive 
bands with silver staining proteins also showed positive 
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Fig. 2. Possible binding domains between Ii-chain and HLA-DR7. The two domains of GG,,,,,, and VT,,,_,z, of cathepsin B that correspond to 
the second and the third active site of cathepsin B are exposed on the surface of the substrate binding crack by X-ray crystallographical data. It is 
well known that the two domains of cystatin B, QL,,, and GS.+73, which show the highest homology with the corresponding two domains of the 
Ii-chain, are binding domains with two active sites of cathepsin B. The domain of VS,,_,g of HLA-DR7 is generally admitted to be desetope to bind 
with the antigenic peptide. 
reactions with the immune staining of the Ii-chain anti- 
body on the SDS-PAGE electrophoresis by Western 
blotting as shown in Fig. 3. The purified Ii-chain gave a 
single component of about 30 kDa mobility on the gel 
under strong reduced condition, while the subunit molec- 
ular weight of the Ii-chain was calculated to be 30 kDa 
from the amino acid sequences by molecular cloning. 
3.3. Interconvertibility of molecular forms of human Ii- 
chain by disulfide bond formation 
When the purified Ii-chain was placed on suitable 
oxide-redox conditions, the Ii-chain converted into four 
different molecular forms of 30, 60, 90 and 120 kDa, 
while the oxidized form showed only a 120 kDa tetramer, 
80 - 
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Fig. 3. Interconversion of molecular forms of purified human Ii-chain. 
The purified Ii-chains under various conditions were subjected to SDS- 
PAGE (l&20% gradient gel with 0.1% SDS). Lanes A, B and C are 
stained with silver; lane A = non-treatment; lane B = mercaptoethanol 
treatment at room temperature; lane C = mercaptoethanol treatment 
at 100°C. Lanes D, E and F are immunoblotting; lane D = non-treat- 
ment; lane E = mercaptoethanol treatment at room temperature; lane 
F = mercaptoethanol treatment at 100°C. 
as shown in Fig. 3. Since the subunit molecular weight 
of the Ii-chain calculated from the primary structure is 
about 30 kDa, including carbohydrates, these bands cor- 
respond to the monomer, dimer, trimer and tetramer of 
the 30 kDa subunit, respectively. Since the human Ii- 
chain contains 2 mol of cysteine residue near the 
N-terminus, the Ii-chain can possibly form logically four 
kinds of molecular types from monomer to tetramer, 
mediated by disulfide bridges depending upon the redox 
potential. However, under the assay conditions of 
cathepsin activities in the presence of 10--1-10-4 M of 
L-cysteine, the human Ii-chain showed mainly a dimer of 
60 kDa as shown in Fig. 4. Therefore, the 60 kDa dimer 
form may be the most stable conformation under acidic 
and reduced conditions in physiological ysosome. While 
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Fig. 4. Dimer of the Ii-chain with L-cysteine is fairly resistant o prote- 
olysis by cathepsin B and cathepsin L. The Ii-chain (450 ng) was incu- 
bated with and without cathepsin B (94 ng) or L (74 ng) in the presence 
of IO-? M L-cysteine for 30 min at 37°C in pH 5.5 acetate buffer 
containing IO-’ M EDTA’2Na. Lane A = non-treatment; lane B = 
L-cysteine treatment; lane C = L-cysteine and cathepsin B treatments; 
lane D = L-cysteine and cathepsin L treatments. 
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Fig. 5. Inhibition profile of cathepsins L, H and B by purified human Ii-chain. The reactions were carried out in 50 mM acetate buffer, pH 5.5, with 
IO-’ M of L-cysteine for 30 min and the released MCA was assayed by fluorometrically. The molar concentrations of the Ii-chain added were calculated 
as 60 kDa dimer form. The K, for cathepsin L was 1.97 x 10m6 and the K, value for Ii-chain was 4.1 x lo-’ M. 
the Ii-chain of rat and mouse contain only 1 mol of 
cysteine residue near N-terminus, these Ii-chains can 
only form logically, monomers and/or dimers. When the 
purified Ii-chain was incubated with cathepsin B or 
cathepsin L in the presence of 10e3 M L-cysteine, the 
Ii-chain was not degraded and showed only the 60 kDa 
dimer form by Western blotting on the SDS-PAGE as 
shown in Fig. 4. It is also already well known that the 
cystatins are not hydrolyzed by cathepsins. Under in- 
tralysosomal conditions of acidic pH and reduced poten- 
tial, the Ii-chain may choose the 60 kDa dimer, and also 
the native dimer form of Ii-chain is not hydrolyzed by 
cathepsin L and B. The binding domains between cys- 
tatin /I and cathepsin B have been well clarified by X-ray 
crystallographical analysis [20,27]. On the other hand, 
cystatins A and C are developed in 10 kDa position on 
the same SDS-PAGE [21] and the antibody for Ii-chain 
does not cross-react with cystatin A and cystatin C (data 
not shown). 
3.4. Inhibition profile of cathepsins by human Ii-chain 
The Ii-chain is considered to be cystatin family from 
the aspect of their sequence homology, as mentioned 
above. The inhibition of cathepsin activities by the Ii- 
chain was then tested directly by purified human Ii-chain 
and various cathepsins in the presence of L-cysteine 
[25,26]. The Ii-chain of 3.8 x lo-’ M inhibited 75% of 
cathepsin L and 55% of H activities, while cathepsin B 
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activity was not inhibited at all, as shown in Fig. 5. The 
inhibition mode of cathepsin L by the Ii-chain shows 
typical competitive kinetics and the Ki value of the 
Ii-chain for cathepsin L was 4.1 x IO-* M. It may consid- 
ered, that the antigen processing by cathepsin B is not 
interfered with by released Ii-chain and also further deg- 
radation of processed antigenic peptides by cathepsin L 
and H may be protected by the released Ii-chain. The 
stereo-mechanisms of binding between cystatin and 
cathepsin B is well established by X-ray crystallographi- 
cal analysis by our studies, and also it is well known that 
the cystatins are not cleaved by cathepsins [6,20-221. 
These data also suggest that the Ii-chain is not cleaved 
by cathepsins judging from the aspect of their similar 
binding mechanism. Furthermore, the purified human 
Ii-chain was not degraded by cathepsin B and cathepsin 
L in the usual reaction conditions with L-cysteine as 
shown in Fig. 4. As we have reported previously, al- 
though the immune responses to high molecular weight 
antigens are inhibited by cathepsin B inhibitors, the im- 
mune responses against the processed antigenic peptide 
are not suppressed by cathepsin B inhibitors [I ,2]. These 
accumulated findings suggest that the cathepsin B inhib- 
itors do not interfere with any processes of immune- 
responses to the antigens by cathepsin B to expose the 
MHC class II surface as suggested in previous papers 
[23,24]. The redox potential and acidic pH in the en- 
dosome may play the most possible role for the release 
of the Ii-chain from MHC class II. 
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